Hsu, Y.-C.; Lin, P.-T.; Teng, W.; Hsieh, Y.-C.; Chen, W.-T.; Su, C.-W.; Wang, C.-T.; Chai, P.-M.; Lin, C.-C.; Lin, C.-Y.;
et al. Comparing Lenvatinib/Pembrolizumab with Atezolizumab/Bevacizumab in Unresectable Hepatocellular Carcinoma: A Real-World Experience with Propensity Score Matching Analysis. Cancers 2024, 16, 3458.
https://doi.org/10.3390/cancers16203458
AMA Style
Hsu Y-C, Lin P-T, Teng W, Hsieh Y-C, Chen W-T, Su C-W, Wang C-T, Chai P-M, Lin C-C, Lin C-Y,
et al. Comparing Lenvatinib/Pembrolizumab with Atezolizumab/Bevacizumab in Unresectable Hepatocellular Carcinoma: A Real-World Experience with Propensity Score Matching Analysis. Cancers. 2024; 16(20):3458.
https://doi.org/10.3390/cancers16203458
Chicago/Turabian Style
Hsu, Yu-Chun, Po-Ting Lin, Wei Teng, Yi-Chung Hsieh, Wei-Ting Chen, Chung-Wei Su, Ching-Ting Wang, Pei-Mei Chai, Chen-Chun Lin, Chun-Yen Lin,
and et al. 2024. "Comparing Lenvatinib/Pembrolizumab with Atezolizumab/Bevacizumab in Unresectable Hepatocellular Carcinoma: A Real-World Experience with Propensity Score Matching Analysis" Cancers 16, no. 20: 3458.
https://doi.org/10.3390/cancers16203458
APA Style
Hsu, Y.-C., Lin, P.-T., Teng, W., Hsieh, Y.-C., Chen, W.-T., Su, C.-W., Wang, C.-T., Chai, P.-M., Lin, C.-C., Lin, C.-Y., & Lin, S.-M.
(2024). Comparing Lenvatinib/Pembrolizumab with Atezolizumab/Bevacizumab in Unresectable Hepatocellular Carcinoma: A Real-World Experience with Propensity Score Matching Analysis. Cancers, 16(20), 3458.
https://doi.org/10.3390/cancers16203458
